News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Wants More Data on Bristol-Myers Squibb Company (BMY) And Otsuka America Pharmaceutical, Inc. Schizophrenia Drug Abilify


9/10/2010 8:00:19 AM

LONDON, Sept 9 (Reuters) - Britain's healthcare cost watchdog said it was unable to recommend use of Bristol-Myers Squibb's (BMY.N) schizophrenia drug Abilify in children aged 15 to 17 and has asked for more information on its effectiveness.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES